The Health Ministry of Brazil has signed a contract on 25 February 2021, to purchase 20 million doses of Covaxin, the COVID-19 vaccine made by India's Bharat Biotech, for delivery between March and May 2021, Reuter's news agency reported on Friday.
In a statement, the Health Ministry said that the deal is worth USD290,000, with the first eight million doses expected to arrive in March 2021.
The Health Ministry added that to speed up the process of buying of COVID-19 vaccines in Brazil and to deal with the COVID-19 outbreak, it had published new rules last week dispensing with the bidding process.
As of 25 February 2021, Brazil reported 1,541 new COVID-19 deaths, the second highest daily death toll since the pandemic began, taking total fatalities to 251,498.
Brazil also added 65,998 new cases, registering a total of 10,390,461 COVID-19 cases, the world's third worst outbreak after the US and India.
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
GC Biopharma granted CMO rights for Curevo Vaccine's shingles vaccine